NAD+ and FDA: compounding, approval and safety

What FDA approval means for this comparison

FDA approval is a product-specific regulatory determination. It should not be inferred from a website mentioning a licensed clinician, a pharmacy or a registered facility. Those statements describe different parts of a service. A buyer needs to know what is being prescribed and dispensed, and whether the seller is describing an approved product or a compounded preparation.

FDA's compounding guidance explains that compounded drugs are not approved and are not reviewed by the agency for safety, effectiveness or quality before marketing. Compounding can meet a medical need, but the existence of that role does not validate every product or every wellness claim. A clear seller should explain the product's status without borrowing the language of approval.

The NAD+ sterile-ingredient warning

FDA has warned that some compounders used food-grade NAD+ to make intravenous products. The agency stated that food-grade ingredients are unsuitable for sterile drug compounding without appropriate processing because of contamination risks. It also described reports of severe chills, shaking, vomiting and fatigue after NAD+ injectable use, with some patients requiring treatment.

This warning concerns ingredient suitability and product quality. It should not be read as proof that every pharmacy's product is contaminated, nor as a complete list of possible adverse effects. The useful response is to ask the prescriber and dispensing pharmacy about the actual preparation and their quality controls. A generic purity claim from a raw-material supplier does not settle the question.

Who is responsible for each part of the service?

A telehealth brand, a clinician group and a dispensing pharmacy may be separate organizations. Before paying, ask which entity provides the clinical evaluation, which pharmacy fills the prescription, and who handles questions or product problems afterward. Clear names and contact routes allow a buyer to verify the relevant licenses and understand where accountability sits.

The same questions apply when a company advertises service across many states. A broad availability claim should not replace confirmation that the clinician and pharmacy can serve your location. This article does not provide a state-by-state legal determination. Requirements and product availability can change, and the entities involved need to confirm the actual arrangement.

What to ask about the product before checkout

Request the exact ingredient, route, dispensing pharmacy, storage information supplied by that pharmacy, and the process for reporting concerns. Ask whether the advertised amount is the complete purchase or an introductory offer, and whether clinical approval is required before a charge becomes nonrefundable. These are practical purchasing questions that should have clear written answers.

Do not accept a claim that a prescription proves an anti-aging, energy or cognitive benefit. A prescribing decision and evidence for a marketed outcome are different questions. Ask what relevant human research supports the exact claim, and whether the product and route match that research. A careful explanation should preserve uncertainty rather than promise a result.

How to interpret a safety assurance

No adverse events in a short study is a narrower statement than safe for everyone. The people included, duration, sample size and method of monitoring matter. Manufacturing quality is another part of the evaluation. A reassuring claim about a molecule does not tell you whether a particular compounded preparation met the appropriate standards.

If a product causes a concerning reaction, seek appropriate medical care and contact the clinician or pharmacy involved. FDA's warning also points patients and professionals toward adverse-event reporting through MedWatch. Retaining the product label, lot and pharmacy details can help a report identify what was actually used. Reporting is separate from assuming that a temporal association proves a particular cause.

• Is the product approved or compounded?
• Which clinician group and pharmacy provide the service?
• What does the quality documentation cover?
• Who handles adverse events, refunds and dispensing questions?

For a practical example, our bmiMD NAD+ review separates advertised services, treatment-specific state restrictions and the pharmacy details a buyer still needs to confirm. Those commercial disclosures do not establish clinical effectiveness.

Sources and scope

These are selected studies and official sources relevant to the question above, rather than a systematic review of every published paper. A finding applies to the people, ingredient, route and outcomes studied. This guide provides education, not a diagnosis or medical advice. Discuss personal treatment decisions with a licensed clinician.

1. U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. Accessed October 2026.
2. U.S. Food and Drug Administration. FDA reminds compounders to use ingredients suitable for sterile compounding. Accessed October 2026.

Continue reading

• NAD+ supplement quality and COAs

  How to match a certificate of analysis to a product and batch, and what quality testing cannot establish.

• NAD+ injection side effects

  Which questions are worth asking depends on the route, and on whether the seller states a dose at all.

• What NAD+ injections are

  A vial and syringes on a subscription, not a clinic drip. What sellers charge for one, how few state the milligrams, and what has been measured in people.

All NAD+ research guides